BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 31907371)

  • 21. Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
    Kong YL; Pan BH; Liang JH; Zhu HY; Wang L; Xia Y; Wu JZ; Fan L; Li JY; Xu W
    Aging (Albany NY); 2020 Aug; 12(16):16083-16098. PubMed ID: 32855355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
    Que Y; Zhang XL; Liu ZX; Zhao JJ; Pan QZ; Wen XZ; Xiao W; Xu BS; Hong DC; Guo TH; Shen LJ; Fan WJ; Chen HY; Weng DS; Xu HR; Zhou PH; Zhang YZ; Niu XH; Zhang X
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of chidamide on human B lymphoma cell lines and its mechanisms].
    Li YY; Wang YF; Wang J; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):893-9. PubMed ID: 22931650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
    Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
    J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chidamide acts on the histone deacetylase-mediated miR-34a/Bcl-2 axis to regulate NB4 cell line proliferation and apoptosis.
    Peng J; Li SJ; Fu X; Liu Y; Zhao XL
    Kaohsiung J Med Sci; 2020 Dec; 36(12):1004-1013. PubMed ID: 32783381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.
    Hayashi K; Nagasaki E; Kan S; Ito M; Kamata Y; Homma S; Aiba K
    Cancer Sci; 2016 May; 107(5):682-9. PubMed ID: 26920337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
    Wang Y; Xue H; Song W; Xiao S; Jing F; Dong T; Wang L
    Hematol Oncol; 2022 Oct; 40(4):617-625. PubMed ID: 35165928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.
    Zhao L; Lv C; Sun L; Li Q; Wang Y; Wu M; Wang Y; Guo Z; Bian S; Kong D; Lin L; Wang Y; Zhou J; Li Y
    Invest New Drugs; 2021 Aug; 39(4):961-970. PubMed ID: 33566253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
    Liu Z; Ding K; Li L; Liu H; Wang Y; Liu C; Fu R
    Biomed Pharmacother; 2016 Oct; 83():1032-1037. PubMed ID: 27541047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
    Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism.
    Li X; He Z; Cheng B; Fang Q; Ma D; Lu T; Wei D; Kuang X; Tang S; Xiong J; Wang J
    Cancer Biol Ther; 2018; 19(9):825-834. PubMed ID: 29969367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF‑κB pathway in multiple myeloma cells.
    Liu Z; Jing Q; Wang Y; Li Y; Mi F; Xiang C; Fu R
    Int J Mol Med; 2019 Jan; 43(1):285-293. PubMed ID: 30387821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.
    Hiraga J; Tomita A; Sugimoto T; Shimada K; Ito M; Nakamura S; Kiyoi H; Kinoshita T; Naoe T
    Blood; 2009 May; 113(20):4885-93. PubMed ID: 19246561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer.
    Zhang N; Sun P; Jin H; Yang Y; Zhao Q; Zhou L; Guo L; Yang X; Lu L
    Anticancer Drugs; 2020 Aug; 31(7):702-708. PubMed ID: 32701251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.
    Thomsen EA; Rovsing AB; Anderson MV; Due H; Huang J; Luo Y; Dybkaer K; Mikkelsen JG
    Mol Oncol; 2020 Sep; 14(9):1978-1997. PubMed ID: 32585766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential of the tumor‑derived extracellular vesicles carrying the miR‑125b‑5p target TNFAIP3 in reducing the sensitivity of diffuse large B cell lymphoma to rituximab.
    Zhang L; Zhou S; Zhou T; Li X; Tang J
    Int J Oncol; 2021 Jun; 58(6):. PubMed ID: 33887878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma.
    Song W; Chen Z; Shi C; Gao Y; Feng X; Li H; Li Z; Zhang M
    Hematol Oncol; 2023 Apr; 41(2):257-266. PubMed ID: 34854108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.
    Tokunaga T; Tomita A; Sugimoto K; Shimada K; Iriyama C; Hirose T; Shirahata-Adachi M; Suzuki Y; Mizuno H; Kiyoi H; Asano N; Nakamura S; Kinoshita T; Naoe T
    Cancer Sci; 2014 Jan; 105(1):35-43. PubMed ID: 24147568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
    Kaneko N; Mitsuoka K; Amino N; Yamanaka K; Kita A; Mori M; Miyoshi S; Kuromitsu S
    Clin Cancer Res; 2014 Apr; 20(7):1814-22. PubMed ID: 24486595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chidamide alleviates TGF-β-induced epithelial-mesenchymal transition in lung cancer cell lines.
    Lin SH; Wang BY; Lin CH; Chien PJ; Wu YF; Ko JL; Chen JJ
    Mol Biol Rep; 2016 Jul; 43(7):687-95. PubMed ID: 27188428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.